Human pathology

Home page > D. Systemic pathology > Genetic and developmental anomalies > Metabolic diseases > Krabbe disease

Krabbe disease

MIM.245200 14q31

globoid cell leukodystrophy, GLD, GCL? globoid cell leukoencephalopathy, galactosylceramide beta-galactosidase deficiency, galactocerebrosidase deficiency, GALC deficiency

Definition: Krabbe disease (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare, often fatal degenerative disorder that affects the myelin sheath of the nervous system.

Krabbe disease is a disease involving the white matter of the central and peripheral nervous systems. While most patients present within the first 6 months of life (?infantile? or ?classic? disease), others present later in life, including in adulthood. Krabbe disease is caused by mutation in the galactosylceramidase gene (GALC) (MIM.606890).

The classic globoid cell leukodystrophy (Krabbe disease) is caused by genetic defects in a lysosomal enzyme, galactosylceramidase. It is one of the two classic genetic leukodystrophies, together with metachromatic leukodystrophies.

The mode of inheritance is autosomal recessive. Typically, the disease occurs among infants and takes a rapidly fatal course, but rarer late-onset forms also exist. Clinical manifestations are exclusively neurologic with prominent white-matter signs.

The pathology is unique, consisting of a rapid and nearly complete disappearance of myelin and myelin-forming cells?the oligodendrocytes in the central nervous system and the Schwann cells in the peripheral nervous system, reactive astroytic gliosis, and infiltration of the unique and often multinucleated macrophages ("globoid cells") that contain strongly periodic acid-Schiff (PAS)-positive materials.

A normally insignificant but highly cytotoxic metabolite, galactosylsphingosine (psychosine), is also a substrate of galactosylceramidase and is considered to play a critical role in the pathogenesis.

The galactosylceramidase gene has been cloned, and a large number of disease-causing mutations have been identified.

Equivalent genetic galactosylceramidase deficiency occurs in several mammalian species, such as mouse, dog, and monkey.

Recently, deficiency of one of the sphingolipid activator proteins, saposin-A, was demonstrated to cause a late-onset, slowly progressive globoid cell leukodystrophy at least in the mouse, with all of the phenotypic consequences of impaired degradation of galactosylceramidase substrates.

Human globoid cell leukodystrophy owing to saposin A deficiency might be anticipated and should be suspected in human patients with a late-onset leukodystrophy with normal galactosylceramidase activity when other possibilities are also excluded.

The only serious attempt at treating human patients is bone marrow transplantation, which can provide significant alleviation of symptoms, particularly in those patients with later-onset, more slowly progressive globoid cell leukodystrophy. (14572137)

See also

- genetic metabolic diseases

References

- Suzuki K.Globoid cell leukodystrophy (Krabbe?s disease): update. J Child Neurol. 2003 Sep;18(9):595-603. PMID: 14572137